Vanguard Global Advisers’s Damora Therapeutics DMRA Stock Holding History
Bought
Maintained
Sold
Other funds holding DMRA
Vanguard Global Advisers's DMRA Position: Q3 2026 in Review
Vanguard Global Advisers increased its Damora Therapeutics (DMRA) stake by 199% in Q3 2026, buying an estimated $358K and bringing the position to 19,043 shares worth $405K. The position accounts for ﹤0.01% of the portfolio, ranked #2187.
Vanguard Global Advisers first reported a position in DMRA in Q1 2026 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.
- Vanguard Global Advisers held 19,043 shares of Damora Therapeutics worth $405K as of Q3 2026.
- Vanguard Global Advisers bought 12,681 Damora Therapeutics shares in Q3 2026, an estimated $358K.
- Damora Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2187 holding.
- Vanguard Global Advisers first reported a position in Damora Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 114 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.